养心康片治疗慢性心力衰竭的临床和实验研究
|
摘要
一、文献研究
本研究在参考国内外文献,了解慢性心力衰竭研究现状基础上,推本溯源,掌握从《黄帝内经》到唐宋元明清时期及现代各医家对心衰病的病因病机及治疗方法的认识,研究了近年来中、西医治疗慢性心力衰竭的方法和成果,为临床和实验研究打下了坚实的理论基础。
二、临床研究
1.目的
客观评价养心康片治疗慢性心力衰竭的临床疗效和安全性,为养心康片获国家批准生产上市提供理论依据。2.方法
以目前公认的慢性心力衰竭治疗方案为对照,开展前瞻性、随机、双盲、多中心对照的临床研究,将纳入病例随机分为对照组和治疗组,对照组给予基础治疗加养心康片模拟片,治疗组给予基础治疗加养心康片,每次3片,每天3次,疗程4周。观察治疗前后心衰患者的心功能、中医证候和明尼苏达生存质量量表的变化。
3.结果
(1)心功能疗效比较,治疗组总有效率为83.5%,对照组总有效率为71.3%,两组的疗效差别有统计学意义(P<0.05)。
(2)中医证候疗效比较,治疗组总有效率为88.7%,对照组总有效率为77.7%,两组的疗效差别有统计学意义(P<0.05)。
(3)两组治疗前后气喘、畏寒肢冷、面浮肢肿和咳嗽咯痰的症状积分比较,治疗后两组的气喘等症状积分都有了明显降低,与治疗前比较,其差别有统计学意义(P<0.01)。治疗组症状积分降低更为明显,治疗后两组的变化值比较差别有统计学意义(P<0.05)。
(4)明尼苏达量表总维度积分和体力维度积分的比较,治疗后两组均有明显的降低,与治疗前比较,其差别有统计学意义(P<0.01)。治疗组积分下降的幅度大于对照组,治疗后两组及两组的变化值比较差别有统计学意义(P<0.01或P<0.05)。
4.结论
(1)养心康片可以改善慢性心力衰竭患者的心功能,减轻临床症状,是治疗慢性心力衰竭的有效药物。
(2)养心康片可以改善慢性心力衰竭患者的中医证候,尤其是在改善心衰患者的气喘、畏寒肢冷、面浮肢肿和咳嗽咯痰方面疗效突出。
(3)养心康片可以增加慢性心力衰竭患者的活动耐量,改善慢性心力衰竭患者的生存质量。
(4)养心康片有良好的安全性和依从性。
三、实验研究
1.目的
观察养心康片对心衰模型兔心脏结构和功能的保护作用及对神经-内分泌系统、炎症因子和血管内皮功能的影响,以及养心康片对心衰模型兔的抗氧化作用,深入探讨养心康片治疗心力衰竭的作用机制,评价养心康在防止心衰动物模型的心室重构和改善心脏收缩同步性方面的疗效。
2.方法
应用结扎兔冠状动脉的方法建立兔心梗后心力衰竭的动物模型,将实验动物分成空白对照组、实验对照组、卡托普利组、养心康片低剂量组、养心康片中剂量组和养心康片高剂量组,分别给予相应的处理措施,连续4周。观察养心康片对心衰模型兔超声心动图、B型尿钠肽(BNP)、心肌肌钙蛋白工(cTnI)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和心肌超微结构等的影响。
3.结果
(1)用药后实验对照组的室间隔(IVS)最薄,空白对照组IVS最厚,其差别有统计学意义(P<0.01)。实验对照组的LVEDd最大,与中剂量组和高剂量组比较,其间差别有统计学意义(P<0.05)。
(2)用药后,实验对照组的LVEF值最低,与中剂量组和高剂量组比较,其间的差别有统计学意义(P<0.01)。
(3)各组间BNP、cTNI比较,实验对照组的值最高,与其他各组比,其间的差别有统计学意义(P<0.05或P<0.01)。
(4)各组间AngⅡ比较,实验对照组的AngⅡ值最高,与其他各组比其间的差别有统计学意义(P<0.05或P<0.01)。
(5)各组间TNF-α比较,空白对照组TNF-α的值最低,与高剂量组相比,TNF-α的差别无统计学意义(P>0.05)。实验对照组TNF-α值最高,与其他各组比较,其间差别有统计学意义(P<0.05或P<0.01)。
(6)各组间ET-1比较,实验对照组的ET-1值最高,与其他各组比较,其间的差别有统计学意义(P<0.01)
(7)各组间IL-6比较,实验对照组IL-6值最高,与其他各组比较,其间差别有统计学意义(P<0.01)。
(8)各组间MDA比较,实验对照组的MDA最高,与其他各组比较差别有统计学意义(P<0.01)。各组间SOD比较,实验对照组SOD的值最低,与空白对照组、中剂量组和高剂量组比较,其间差别有统计学意义(P<0.05或P<0.01)。
(9)各组间凋亡指数的比较,空白对照组的凋亡指数最小,实验对照组的凋亡指数最大,各组间比较,其差别均有统计学意义(P<0.05或P<0.01)。
(10)用药后,实验对照组的Tvr-SD最高,空白对照组的Tvr-SD最低,与其他各组比较,其间差别有统计学意义(P<0.05或P<0.01)。
(11)电镜结果显示高剂量组肌小节可见,肌原纤维排列整齐,肌节结构基本清楚,肌丝尚完整,明暗带结构较清晰,可见Z线、M线。线粒体及肌浆网,数量增多,结构正常。嵴结构基本清楚。细胞核核膜清楚,染色质分布基本正常。而实验对照组的肌小节变形,肌丝断裂,排列紊乱,肌膜水肿。线粒体增多,嵴消失,内质网扩张,部分肌细胞崩解,明暗带结构模糊,Z线增粗,M线不清晰。细胞核核膜部分溶解、消失,边缘欠规则,染色质分布异常。
4.结论：
(1)结扎兔冠状动脉可以复制心梗后心衰模型,操作步骤相对简单,成功率较高。
(2)养心康片可以提高心衰模型兔的心功能,降低血清BNP、cTnI水平。
(3)养心康片可以防止心衰模型兔的室间隔变薄,减少其舒张末容积,降低心脏指数,改善心脏的超微结构,有防止心衰模型兔心室重构的作用。
(4)养心康片可以降低心衰模型兔的血清AngⅡ的水平,可以阻断其神经-内分泌系统的激活。
(5)养心康可以降低心衰模型兔血清的TNF-α、IL-6水平,表明养心康片具有抗炎症因子的作用。
(6)养心康片可以降低心衰模型兔血清的ET-1水平,有改善血管内皮功能的作用。
(7)养心康片可以降低心衰模型兔血清的MDA水平,升高血清的SOD水平,表明养心康片具有抗氧化作用。
(8)养心康片可以减少心衰模型兔心肌细胞的凋亡。
(9)养心康具有改善心衰模型兔心脏收缩同步性的作用。
Part one Literature Research
This research based on referring to domestic and international literature and observing the current research situation of chronic heart failure (CHF) and mastered the cognition of etiology, pathogenesis, treatment of CHF from the period of Huangdineijing to tang, song, yuan, ming, qing dynasty and the clinical experience of modern traditional Chinese physician. We also summarized the research method and achievements of TCM and western medicine in treating CHF for the past few years and provided solid theory support for clinical and experimental study.
Part two Clinical Research
1.Objective
To objectively evaluate clinical effect and safety on treatment of CHF using yangxinkang tablet and to provide the theoretical basis for yangxinkang tablet being approved by the State for production and sale.
2. Method
Taking the currently accepted treatment of CHF as a control, We carried out a prospective, randomized, double-blind, multi-center controlled clinical study. Cases included in this study were randomly divided into control group and treatment group. Cases of control group received basic therapy plus analog Yangxinkang tablet, and cases of treatment group received basic therapy plus Yangxinkang tablet,3 tablets each time,3 times each day, for 4 weeks. We observed the changes in cardiac function, TCM Syndroms, and Minnesota Satisfaction Questionnaire Scales of patients with heart failure before and after treatment.
3. Result
(1) comparison of curative effect on cardiac function:the total effective rate was 83.5% in the treatment group and 71.3% in the control group, and there was a statistically significant difference in efficacy between the two groups (P<0.05)
(2) comparison of curative effect on TCM Syndroms:the total effective rate was 88.7% in the treatment group and 77.7% in the control group, and there was a statistically significant difference in efficacy between the two groups (P<0.05)
(3) comparison of symptoms scores of gasp, fear of cold and cold in the extremities, swollen of face and limbs, cough and expectoration:after treatment, symptom scores of two groups had a significantly lower, and comparing with before treatment, the difference was statistically significant (P<0.01).Symptom scores in treatment group decreased more significantly, and there were statistically significant differences in the change value between the two groups (P<0.05)
(4) comparison of total dimension scores and physical dimension scores of Minnesota Satisfaction Questionnaire Scale:after treatment, scores of two groups had a significantly lower, and comparing with before treatment, the difference was statistically significant (P<0.01). Scores of treatment group decreased more significantly than that of control group, and there were statistically significant difference in scores after treatment and in the change value between the two groups (P<0.01 or P<0.05)
4. Conclusion
(1) Yangxinkang tablet can improve cardiac function and relieve clinical symptoms of patients with CHF, so it is an effective drug for treating CHF.
(2) Yangxinkang tablet can improve TCM syndrome of patients with CHF, and especially in the improvement of gasp, fear of cold and cold in the extremities, swollen of face and limbs, cough and expectoration is highly effective.
(3) Yangxinkang tablet can increase exercise tolerance in patients with CHF, and improve the life quality of patients with CHF.
(4) Yangxinkang tablet possess good security and compliance.
Part three Experimental Research
1. Objective
Observed the protective effect of yangxinkang tablet for heart structure and function of rabbit model with CHF and it's influence on neuroendocrine system, inflammation factor, endothelial function and antioxidation. In-depth investigated the mechanism of action of Yangxinkang tablets in the treatment of heart failure. Evaluated effect in preventing ventricular remodeling and systolic asynchronous of animal model of heart failure by Yangxinkang tablet.
2. Method
Making heart failure animal model by blocking rabbit left anterior descending coronary artery. The experimental animals were divided into control group, experimental control group, captopril group, Yangxinkang tablet low dose group, Yangxinkang tablet middle dose group and Yangxinkang tablet high dose group, and were given appropriate treatment measures for 4 weeks. Investgated the effects of yangxinkang tablet on echocardiography, B-type natriuretic peptide (BNP), Cardiac troponin I (cTnⅠ), Interleukin-6 (IL-6) Tumor necrosis factor-α(TNF-α) and myocardial ultrastructure,etc. of rabbit model with heart failure.
3. Result
(1) After treatment, the interventricular septum (IVS) of experimental control group was thinnest, the interventricular septum (IVS) of control group was thickest, the difference between them was statistically significant (P< 0.01). The LVEDd of experimental control group was maximum, compared with that of middle dose group and high dose group, the difference among them were statistically significant(P<0.05).
(2) After treatment, the LVEF of experimental control group was lowest, compared with that of middle dose group and high dose group, the differences among them were statistically significant(P<0.01).
(3) Comparison of BNP and cTNI in each groups, the experimental control group is highest, compared with other groups, the differences among them were statistically significant(P<0.05 or P<0.01).
(4) Comparison of AngⅡin each groups, the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.05 or P<0.01).
(5) Comparison of TNF-αin each groups, the control group was lowest, compared with high dose group, the difference between them was not statistically significant(P>0.05). the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.05或P<0.01).
(6) Comparison of ET-1 in each groups, the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.01).
(7) Comparison of IL-6 in each groups, the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.01).
(8) Comparison of MDA in each groups, the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.01). Comparison of SOD in each groups, the experimental control group is lowest, compared with control group, middle dose group and high dose group, the differences among them were statistically significant(P<0.01).
(9) Comparison of apoptosis index in each groups, the control group was lowest, the experimental control group was highest, compared with each groups, the differences among them were statistically significant (P<0.05 or P<0.01)
(10) After treatment, the Tvr-SD of experimental control group was highest, the Tvr-SD of control group was lowest, compared with other groups, the differences among them were statistically significant (P<0.05 or P<0.01)
(11) Results of transmission electron microscopy:in the high dose group, sarcomere can be found, myofibrils aligned regularly, Sarcomere structure was basically clear, myofilament were still intact, isotropic and anisotropic band structure were also clear, Z and M line can also be found. The number of mitochondria and sarcoplasmic reticulum increased, the structure of them were normal. The structure of crista and the nuclear membrane were clearly. The distribution of chromatin was basically normal. But in the experimental control group, the sarcomere was deformed, myofilament was fractured and disordered, sarcolemma was edema, the number of mitochondria increased, crista disappeared, endoplasmic reticulum distended, part of the muscle cell disintegrated, isotropic and anisotropic band structure were illegible, Z line was thickened, M line was illegible. The nuclear membrane were partly dissolved and disappeared, the edge of the nuclear membrane was irregular. The distribution of chromatin was abnormal.
4. Conclusion
(1) Blocking rabbit left anterior descending coronary artery can make heart failure animal model, and it's operating procedures was relatively simple and Success rate was higher.
(2) Yangxinkang tablet can improve cardiac function of rabbit model with heart failure and reduce serum BNP, cTnⅠlevels.
(3)Yangxinkang tablet can prevent IVS of rabbit model with heart failure thinning, reduce the diastolic volume and cardiac index, improve the heart ultrastructure, and prevent ventricular remodeling in rabbit model with heart failure.
(4) Yangxinkang tablet can reduce serum AngⅡlevels of rabbit model with heart failure, and block the nerve-endocrine system's activation.
(5) Yangxinkang tablet can reduce serum TNF-α、IL-6 levels of rabbit model with heart failure and be against inflammation factors.
(6) Yangxinkang tablet can reduce serum ET-1 levels of rabbit model with heart failure, improve endothelial function.
(7) Yangxinkang tablet can reduce serum MDA levels and elevate serum SOD levels of rabbit model with heart failure, and it is with antioxidant effect.
(8) Yangxinkang tablet can reduce apoptosis of myocardial of rabbit model with heart failure.
(9) Yangxinkang tablet can improve systolic synchronous of rabbit model with heart failure.
本研究在参考国内外文献,了解慢性心力衰竭研究现状基础上,推本溯源,掌握从《黄帝内经》到唐宋元明清时期及现代各医家对心衰病的病因病机及治疗方法的认识,研究了近年来中、西医治疗慢性心力衰竭的方法和成果,为临床和实验研究打下了坚实的理论基础。
二、临床研究
1.目的
客观评价养心康片治疗慢性心力衰竭的临床疗效和安全性,为养心康片获国家批准生产上市提供理论依据。2.方法
以目前公认的慢性心力衰竭治疗方案为对照,开展前瞻性、随机、双盲、多中心对照的临床研究,将纳入病例随机分为对照组和治疗组,对照组给予基础治疗加养心康片模拟片,治疗组给予基础治疗加养心康片,每次3片,每天3次,疗程4周。观察治疗前后心衰患者的心功能、中医证候和明尼苏达生存质量量表的变化。
3.结果
(1)心功能疗效比较,治疗组总有效率为83.5%,对照组总有效率为71.3%,两组的疗效差别有统计学意义(P<0.05)。
(2)中医证候疗效比较,治疗组总有效率为88.7%,对照组总有效率为77.7%,两组的疗效差别有统计学意义(P<0.05)。
(3)两组治疗前后气喘、畏寒肢冷、面浮肢肿和咳嗽咯痰的症状积分比较,治疗后两组的气喘等症状积分都有了明显降低,与治疗前比较,其差别有统计学意义(P<0.01)。治疗组症状积分降低更为明显,治疗后两组的变化值比较差别有统计学意义(P<0.05)。
(4)明尼苏达量表总维度积分和体力维度积分的比较,治疗后两组均有明显的降低,与治疗前比较,其差别有统计学意义(P<0.01)。治疗组积分下降的幅度大于对照组,治疗后两组及两组的变化值比较差别有统计学意义(P<0.01或P<0.05)。
4.结论
(1)养心康片可以改善慢性心力衰竭患者的心功能,减轻临床症状,是治疗慢性心力衰竭的有效药物。
(2)养心康片可以改善慢性心力衰竭患者的中医证候,尤其是在改善心衰患者的气喘、畏寒肢冷、面浮肢肿和咳嗽咯痰方面疗效突出。
(3)养心康片可以增加慢性心力衰竭患者的活动耐量,改善慢性心力衰竭患者的生存质量。
(4)养心康片有良好的安全性和依从性。
三、实验研究
1.目的
观察养心康片对心衰模型兔心脏结构和功能的保护作用及对神经-内分泌系统、炎症因子和血管内皮功能的影响,以及养心康片对心衰模型兔的抗氧化作用,深入探讨养心康片治疗心力衰竭的作用机制,评价养心康在防止心衰动物模型的心室重构和改善心脏收缩同步性方面的疗效。
2.方法
应用结扎兔冠状动脉的方法建立兔心梗后心力衰竭的动物模型,将实验动物分成空白对照组、实验对照组、卡托普利组、养心康片低剂量组、养心康片中剂量组和养心康片高剂量组,分别给予相应的处理措施,连续4周。观察养心康片对心衰模型兔超声心动图、B型尿钠肽(BNP)、心肌肌钙蛋白工(cTnI)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和心肌超微结构等的影响。
3.结果
(1)用药后实验对照组的室间隔(IVS)最薄,空白对照组IVS最厚,其差别有统计学意义(P<0.01)。实验对照组的LVEDd最大,与中剂量组和高剂量组比较,其间差别有统计学意义(P<0.05)。
(2)用药后,实验对照组的LVEF值最低,与中剂量组和高剂量组比较,其间的差别有统计学意义(P<0.01)。
(3)各组间BNP、cTNI比较,实验对照组的值最高,与其他各组比,其间的差别有统计学意义(P<0.05或P<0.01)。
(4)各组间AngⅡ比较,实验对照组的AngⅡ值最高,与其他各组比其间的差别有统计学意义(P<0.05或P<0.01)。
(5)各组间TNF-α比较,空白对照组TNF-α的值最低,与高剂量组相比,TNF-α的差别无统计学意义(P>0.05)。实验对照组TNF-α值最高,与其他各组比较,其间差别有统计学意义(P<0.05或P<0.01)。
(6)各组间ET-1比较,实验对照组的ET-1值最高,与其他各组比较,其间的差别有统计学意义(P<0.01)
(7)各组间IL-6比较,实验对照组IL-6值最高,与其他各组比较,其间差别有统计学意义(P<0.01)。
(8)各组间MDA比较,实验对照组的MDA最高,与其他各组比较差别有统计学意义(P<0.01)。各组间SOD比较,实验对照组SOD的值最低,与空白对照组、中剂量组和高剂量组比较,其间差别有统计学意义(P<0.05或P<0.01)。
(9)各组间凋亡指数的比较,空白对照组的凋亡指数最小,实验对照组的凋亡指数最大,各组间比较,其差别均有统计学意义(P<0.05或P<0.01)。
(10)用药后,实验对照组的Tvr-SD最高,空白对照组的Tvr-SD最低,与其他各组比较,其间差别有统计学意义(P<0.05或P<0.01)。
(11)电镜结果显示高剂量组肌小节可见,肌原纤维排列整齐,肌节结构基本清楚,肌丝尚完整,明暗带结构较清晰,可见Z线、M线。线粒体及肌浆网,数量增多,结构正常。嵴结构基本清楚。细胞核核膜清楚,染色质分布基本正常。而实验对照组的肌小节变形,肌丝断裂,排列紊乱,肌膜水肿。线粒体增多,嵴消失,内质网扩张,部分肌细胞崩解,明暗带结构模糊,Z线增粗,M线不清晰。细胞核核膜部分溶解、消失,边缘欠规则,染色质分布异常。
4.结论：
(1)结扎兔冠状动脉可以复制心梗后心衰模型,操作步骤相对简单,成功率较高。
(2)养心康片可以提高心衰模型兔的心功能,降低血清BNP、cTnI水平。
(3)养心康片可以防止心衰模型兔的室间隔变薄,减少其舒张末容积,降低心脏指数,改善心脏的超微结构,有防止心衰模型兔心室重构的作用。
(4)养心康片可以降低心衰模型兔的血清AngⅡ的水平,可以阻断其神经-内分泌系统的激活。
(5)养心康可以降低心衰模型兔血清的TNF-α、IL-6水平,表明养心康片具有抗炎症因子的作用。
(6)养心康片可以降低心衰模型兔血清的ET-1水平,有改善血管内皮功能的作用。
(7)养心康片可以降低心衰模型兔血清的MDA水平,升高血清的SOD水平,表明养心康片具有抗氧化作用。
(8)养心康片可以减少心衰模型兔心肌细胞的凋亡。
(9)养心康具有改善心衰模型兔心脏收缩同步性的作用。
Part one Literature Research
This research based on referring to domestic and international literature and observing the current research situation of chronic heart failure (CHF) and mastered the cognition of etiology, pathogenesis, treatment of CHF from the period of Huangdineijing to tang, song, yuan, ming, qing dynasty and the clinical experience of modern traditional Chinese physician. We also summarized the research method and achievements of TCM and western medicine in treating CHF for the past few years and provided solid theory support for clinical and experimental study.
Part two Clinical Research
1.Objective
To objectively evaluate clinical effect and safety on treatment of CHF using yangxinkang tablet and to provide the theoretical basis for yangxinkang tablet being approved by the State for production and sale.
2. Method
Taking the currently accepted treatment of CHF as a control, We carried out a prospective, randomized, double-blind, multi-center controlled clinical study. Cases included in this study were randomly divided into control group and treatment group. Cases of control group received basic therapy plus analog Yangxinkang tablet, and cases of treatment group received basic therapy plus Yangxinkang tablet,3 tablets each time,3 times each day, for 4 weeks. We observed the changes in cardiac function, TCM Syndroms, and Minnesota Satisfaction Questionnaire Scales of patients with heart failure before and after treatment.
3. Result
(1) comparison of curative effect on cardiac function:the total effective rate was 83.5% in the treatment group and 71.3% in the control group, and there was a statistically significant difference in efficacy between the two groups (P<0.05)
(2) comparison of curative effect on TCM Syndroms:the total effective rate was 88.7% in the treatment group and 77.7% in the control group, and there was a statistically significant difference in efficacy between the two groups (P<0.05)
(3) comparison of symptoms scores of gasp, fear of cold and cold in the extremities, swollen of face and limbs, cough and expectoration:after treatment, symptom scores of two groups had a significantly lower, and comparing with before treatment, the difference was statistically significant (P<0.01).Symptom scores in treatment group decreased more significantly, and there were statistically significant differences in the change value between the two groups (P<0.05)
(4) comparison of total dimension scores and physical dimension scores of Minnesota Satisfaction Questionnaire Scale:after treatment, scores of two groups had a significantly lower, and comparing with before treatment, the difference was statistically significant (P<0.01). Scores of treatment group decreased more significantly than that of control group, and there were statistically significant difference in scores after treatment and in the change value between the two groups (P<0.01 or P<0.05)
4. Conclusion
(1) Yangxinkang tablet can improve cardiac function and relieve clinical symptoms of patients with CHF, so it is an effective drug for treating CHF.
(2) Yangxinkang tablet can improve TCM syndrome of patients with CHF, and especially in the improvement of gasp, fear of cold and cold in the extremities, swollen of face and limbs, cough and expectoration is highly effective.
(3) Yangxinkang tablet can increase exercise tolerance in patients with CHF, and improve the life quality of patients with CHF.
(4) Yangxinkang tablet possess good security and compliance.
Part three Experimental Research
1. Objective
Observed the protective effect of yangxinkang tablet for heart structure and function of rabbit model with CHF and it's influence on neuroendocrine system, inflammation factor, endothelial function and antioxidation. In-depth investigated the mechanism of action of Yangxinkang tablets in the treatment of heart failure. Evaluated effect in preventing ventricular remodeling and systolic asynchronous of animal model of heart failure by Yangxinkang tablet.
2. Method
Making heart failure animal model by blocking rabbit left anterior descending coronary artery. The experimental animals were divided into control group, experimental control group, captopril group, Yangxinkang tablet low dose group, Yangxinkang tablet middle dose group and Yangxinkang tablet high dose group, and were given appropriate treatment measures for 4 weeks. Investgated the effects of yangxinkang tablet on echocardiography, B-type natriuretic peptide (BNP), Cardiac troponin I (cTnⅠ), Interleukin-6 (IL-6) Tumor necrosis factor-α(TNF-α) and myocardial ultrastructure,etc. of rabbit model with heart failure.
3. Result
(1) After treatment, the interventricular septum (IVS) of experimental control group was thinnest, the interventricular septum (IVS) of control group was thickest, the difference between them was statistically significant (P< 0.01). The LVEDd of experimental control group was maximum, compared with that of middle dose group and high dose group, the difference among them were statistically significant(P<0.05).
(2) After treatment, the LVEF of experimental control group was lowest, compared with that of middle dose group and high dose group, the differences among them were statistically significant(P<0.01).
(3) Comparison of BNP and cTNI in each groups, the experimental control group is highest, compared with other groups, the differences among them were statistically significant(P<0.05 or P<0.01).
(4) Comparison of AngⅡin each groups, the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.05 or P<0.01).
(5) Comparison of TNF-αin each groups, the control group was lowest, compared with high dose group, the difference between them was not statistically significant(P>0.05). the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.05或P<0.01).
(6) Comparison of ET-1 in each groups, the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.01).
(7) Comparison of IL-6 in each groups, the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.01).
(8) Comparison of MDA in each groups, the experimental control group was highest, compared with other groups, the differences among them were statistically significant(P<0.01). Comparison of SOD in each groups, the experimental control group is lowest, compared with control group, middle dose group and high dose group, the differences among them were statistically significant(P<0.01).
(9) Comparison of apoptosis index in each groups, the control group was lowest, the experimental control group was highest, compared with each groups, the differences among them were statistically significant (P<0.05 or P<0.01)
(10) After treatment, the Tvr-SD of experimental control group was highest, the Tvr-SD of control group was lowest, compared with other groups, the differences among them were statistically significant (P<0.05 or P<0.01)
(11) Results of transmission electron microscopy:in the high dose group, sarcomere can be found, myofibrils aligned regularly, Sarcomere structure was basically clear, myofilament were still intact, isotropic and anisotropic band structure were also clear, Z and M line can also be found. The number of mitochondria and sarcoplasmic reticulum increased, the structure of them were normal. The structure of crista and the nuclear membrane were clearly. The distribution of chromatin was basically normal. But in the experimental control group, the sarcomere was deformed, myofilament was fractured and disordered, sarcolemma was edema, the number of mitochondria increased, crista disappeared, endoplasmic reticulum distended, part of the muscle cell disintegrated, isotropic and anisotropic band structure were illegible, Z line was thickened, M line was illegible. The nuclear membrane were partly dissolved and disappeared, the edge of the nuclear membrane was irregular. The distribution of chromatin was abnormal.
4. Conclusion
(1) Blocking rabbit left anterior descending coronary artery can make heart failure animal model, and it's operating procedures was relatively simple and Success rate was higher.
(2) Yangxinkang tablet can improve cardiac function of rabbit model with heart failure and reduce serum BNP, cTnⅠlevels.
(3)Yangxinkang tablet can prevent IVS of rabbit model with heart failure thinning, reduce the diastolic volume and cardiac index, improve the heart ultrastructure, and prevent ventricular remodeling in rabbit model with heart failure.
(4) Yangxinkang tablet can reduce serum AngⅡlevels of rabbit model with heart failure, and block the nerve-endocrine system's activation.
(5) Yangxinkang tablet can reduce serum TNF-α、IL-6 levels of rabbit model with heart failure and be against inflammation factors.
(6) Yangxinkang tablet can reduce serum ET-1 levels of rabbit model with heart failure, improve endothelial function.
(7) Yangxinkang tablet can reduce serum MDA levels and elevate serum SOD levels of rabbit model with heart failure, and it is with antioxidant effect.
(8) Yangxinkang tablet can reduce apoptosis of myocardial of rabbit model with heart failure.
(9) Yangxinkang tablet can improve systolic synchronous of rabbit model with heart failure.
引文
[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国部分地区1980、1990、2000年慢性心力衰竭住院病例回顾性调查[J].中华心血管病杂志,2002；30：450-454.
[2]严萍,黄飞翔,林求诚,等.B型尿钠肽与充血性心力衰竭中医辨证分型的关系[J].中西医结合心脑血管病杂志,2007；5(5)：380-381.
[3]周杰,高晓玲,张宝州.充血性心力衰竭患者心钠素与中医辨证分型相关性的临床研究[J].中华实用中西医杂志,2003；3(8)：1037-1039.
[4]安辉,林凯旋,缪灿铭.充血性心力衰竭甲状腺激素及中医辨证与疗效相关性的临床研究[J].中国中医药信息杂志,2004；11(7)：618-619.
[5]刘革命,熊尚全,马成富.慢性心力衰竭中医辨证分型与血浆NO及TNF-α含量的关系[J].山东中医杂志,2004；23(2)：71-72.
[6]宋雅芳,杨培君,王瑞莉.仙人救心片对充血性心力衰竭大鼠神经内分泌调节作用的实验研究[J].现代中医药,2006；26(4)：64-65.
[7]朱章志,龙新生.加味真武汤对充血性心衰模型血流动力学及血管紧张素Ⅱ的影响[J].中药新药与临床药理.2001,12(5)：342-345.
[8]张一昕,张志霞,李国川,等.人参强心滴丸对心衰大鼠肾素-血管紧张素-醛固酮系统的影响[J].中药药理与临床,2007；23(2)：70-71.
[9]刘革命,丁磊,谢艳玲,等.康达心口服液对慢性心力衰竭患者血浆肾素-血管紧张素-醛固酮系统的影响[J].吉林中医药,2005；25(4)：12-13.
[10]Greenberg B. J Treatment of heart failure:state of the art and prospectives[J]. J Cardiovasc Pharmacol,2001; 38:S59-S63.
[11]黄飞翔,叶盈,蔡晶,等.健心颗粒干预大鼠慢性心力衰竭左室重构的实验研究[J].中西医结合心脑血管病杂志,2006；4(9)：780-782.
[12]魏聪,贾振华,吴以岭,等.芪苈强心胶囊对兔实验性慢性心力衰竭心室重构的保护作用[J].疑难病杂志,2007；6(3)：144-147.
[13]赵明镜,王硕仁,李敏,等.早期应用活血和益气中药抑制心衰大鼠左室重构和凋亡的对比研究[J].中国中药杂志,2007；32(8)：710-714.
[14]刘革命,郭新侠,谢艳玲,等.温阳益气、活血利水法对慢性心力衰竭左室重构的影响[J].上海中医药杂志,2005；39(5)：20-21.
[15]冼绍祥,欧明.肾阳虚型慢性充血性心力衰竭与TNF-α和IL-6的关系研究[J].实用中医内科杂志,2006；20(6)：564-565.
[16]朱奔奔,郭维,黄亮,等.真武汤对慢性充血性心力衰竭模型大鼠ET、CGRP水平的影响[J].江苏中医药,2005；26(8)：49-51.
[17]黄衍寿,冼绍祥,周名璐,等.养心康对心肌肥大型心力衰竭大鼠血浆ET、CGRP 含量的影响[J].广州中医药大学学报,2002；19(1)：40-42.
[18]王敬民,金炜,孙秀笺.参麦注射液对心力衰竭患者血ET及TNF-α的影响[J].浙江中西医结合杂志,2004；14(1)：4-6.
[19]Li Z, Bimg OH, long X, et al. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat[J]. Am J Physiol,1997; 272:H2313.
[20]方显明,韦斌,郎中云.安心颗粒对心力衰竭大鼠细胞凋亡基因Bcl—2及Fas表达的影响[J].中西医结合心脑血管病杂志,2007；5(8)：701-702.
[21]李敏,王硕仁,赵明镜,等.活血益气方药对心肌梗死后心力衰竭大鼠心肌细胞凋亡的影响[J].中西医结合心脑血管病杂志,2005；3(1)：33-35.
[22]陈兆善,董耀荣,周华,等.强心合剂对慢性心力衰竭大鼠心肌细胞凋亡的影响[J].上海中医药大学学报,2004；18(1)：42-45.
[23]刘艳,陈丽云,章忱.慢性心力衰竭中医证型的文献分析[J].上海中医药大学学报,2008；22(4)：43-46.
[24]邓铁涛.治疗心力衰竭的思路与方法[J].新中医,1995； (1)：6-8.
[25]邹旭,刘泽银,潘光明.暖心胶囊治疗慢性充血性心力衰竭的远期疗效观察[J].上海中医药杂志,2006；40(2)：6-7.
[26]杨培君,杨磊.充血性心力衰竭的中医治疗概要[J].陕西中医学院学报,2002；25(1)：2-5.
[27]陈长华.辨证施治心力衰竭50例[J].福建中医学院学报,1995；5(1)：14-15.
[28]谢乐.中医分型治疗充血性心力衰竭77例[J].四川中医,2002；20(6)：41.
[29]张瑞华,焦增绵,马丽红,等.慢性充血性心力衰竭的中医辨证论治[J].中国医药学报,2002；17(17)：440.
[30]王双乾,梁栋贤.心衰饮治疗心力衰竭32例[J].陕西中医,2002；23(6)：506.
[31]吴勉华.养心通脉合剂治疗充血性心力衰竭临床研究[J].山东中医杂志,2001；20(12)：715-718.
[32]张万义,邱云卿,张万芬.升补宗气法治疗老年慢性充血性心力衰竭疗效观察[J].中国中西医结合杂志,2004；24(1)：43.
[33]郑军.温阳利水法治疗慢性心力衰竭48例[J].陕西中医,2005；26(2)：102-103.
[34]赵惠,李七一.真武汤加味治疗慢性充血性心力衰竭40例[J].南京中医药大学学报,2005；21(6)：355-356.
[35]孙媛.中西医结合治疗慢性充血性心力衰竭32例[J].吉林中医药,2005；25(6)：32-33.
[36]李金红.中西医结合治疗充血性心力衰竭临床观察[J].辽宁中医杂志,2006；33(7)：860-861.
[37]朱丽华,倪国瑞.中西医结合治疗慢性心力衰竭30例疗效观察[J].新中医,2007；39(11)：17-18.
[38]陈勇.加味真武汤治疗慢性心衰50例临床观察[J].光明中医,2006；21(7)：34-36.
[39]王敏生.温阳强心汤治疗慢性心衰30例[J].实用中医内科杂志,2005；19(6)：557.
[40]杨勇娟.黄芪注射液结合西药治疗充血性心力衰竭的疗效观察[J]. World Health Digest,2007; 4 (11):31-32.
[41]孟捍华,马敏杰.黄芪注射液对慢性充血性心力衰竭治疗作用的观察[J].中医药临床杂志,2008；20(1)：41-42.
[42]张继明,侯召荣.培哚普利加黄芪注射液治疗难治性心力衰竭疗效观察[J].中国心血管杂志,2006；11(6)：451-453.
[43]刘英芹,李芸.黄芪注射液治疗充血性心力衰竭临床研究[J].实用中医药杂志,2005：21(4)：198-199.
[44]李有亮.川芎嗪联合黄芪治疗慢性肺心病并发心衰患者52例临床观察[J].中华现代内科学杂志,2004；1(5)：56-58.
[45]程勇,郑金荣,王兵,等.川芎嗪治疗56例肺心病心衰患者的临床观察[J].中原医刊,2007；34(5)：77-78.
[46]吴晓玲.葶苈子水提物对狗左心室功能的作用[J].中药材,1998；21(5)：243-245.
[47]柏正平.复方葶苈子胶囊对肺动脉高压和心肌力影响的实验研究[J].湖南中医杂志,2000：16(1)：57.
[48]戚文航.心力衰竭的流行病学及治疗进展[J].现代实用医学,2004；16(11)：632-634.
[49]Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol,1993; 22(supplA):6A-13A.
[50]Michael B. Circulation,2003; 107:11002-11021.
[51]魏晓萍,陈雅慧,惠起源.β3肾上腺素能受体与心血管疾病[J].心血管病学进展,2005；26(2)：204-206.
[52]李为民,孔一慧,薛竟宜,田颖.NG-硝基-L-精氨酸甲基酯对心力衰竭大鼠应用β3受体激动剂后血流动力学和β受体mRNA表达水平的影响[J].中华心血管病杂志,2005：33(6)：509-512.
[53]李美霞,王晓樑,汤嘉宁,等.心力衰竭患者抗β3肾上腺素能受体自身抗体的分布及特性[J].中华心血管病杂志,2005；33(12)：1114-1119.
[54]富路,葛海龙,李佳,等.慢性心力衰竭患者血钠水平与血浆肾素活性、抗利尿激素、脑利钠肽的关系[J].中华心血管病杂志,2006；34(9)：781-783.
[55]王礼春,马虹,何建桂,等.培哚普利对心力衰竭大鼠心肌细胞钙瞬变及其调控蛋白的影响[J].中华心血管病杂志,2005；33(6)：513-518.
[56]杨永健,朱文玲,周兴文,等.钙蛋白酶参与心力衰竭患者心肌重构的信号传导[J].中华心血管病杂志,2005；33(3)：247-250.
[57]杨永健,张鑫,朱文玲,等.钙调神经磷酸酶信号通路参与充血性心力衰竭患者心肌重塑的机制[J].中国循环杂志,2006；21(4)：291-293.
[58]刘尊齐,崔连群.慢性心力衰竭患者血清肌钙蛋白Ⅰ与心肌重构的相关性研究[J].中华心血管病杂志,2006；34(5)：437-439.
[59]郭豫涛,李小鹰,吴迪,等.骨髓干细胞移植通过基质金属蛋白酶及其抑制剂降低大鼠缺血性心力衰竭心室重构[J].中华心血管病杂志,2006；34(9)：784-788.
[60]Foo RS, Mani K, Kitsis RN. Death begets failure in the heart[J]. J Clin Invest,2005; 115(3):565-571.
[61]Merkle S, Frantz S, Schon MP, et al. A role for caspase-1 in heart failure[J]. Cite Res,2007; 100(5):645-653.
[62]Yam aguchiH, Yoshida J, Y am am o to K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy [J]. J Am CollCardiol,2004; 43:55-60.
[63]崔红玉,王曼,赵常艳,等.B型尿钠肽与不同心功能分级的充血性心力衰竭的关系[J].中国心血管杂志,2005；10(5)：317-318.
[64]汪芳,李卫,黄洁,等.血浆N末端原脑利钠肽水平对慢性心力衰竭患者长期预后的预测价值[J].中华心血管病杂志,2006；34(1)：28-32.
[65]初红霞,陶志刚,梁荔燕.心力衰竭患者血清血管内皮生长因子和C-反应蛋白的变化及意义[J].中国心血管杂志,2006；11(6)：439-442.
[66]Sun M, Chen M, Dawood F, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state[J]. Circulation,2007; 115(11):1398-1407.
[67]Handek SB, Taffet GE, Schneider MD, et al. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways[J]. J Clin Invest,2007; 117(9):2692-2701.
[68]李安莹,谭茗月,赵水平.心力衰竭患者循环血中肿瘤坏死因子-α、白细胞介素-6、高敏C反应蛋白水平的变化及阿托伐他汀的干预作用[J].中国循环杂志,2006；21(6)：435-437.
[69]任骞,刘玉杰.充血性心力衰竭患者甲状腺激素异常变化及其临床意义[J].中国心血管杂志,2006；11(3)：189-190.
[70]中华医学会心血管病学分会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂 志,2007；35(12)：1076-1095.
[71]Brown NJ. AgirbastiMA. Williams GH. et al. Effect of Activation and Inhibition of Renin-angiotension System on Plasma PAF1[J]. Hyperten slon, 1998; 32 (6):965-971.
[72]孟伟栋, 汪爱虎.醛固酮及拮抗剂在心力衰竭中的研究进展[J].国外医学心血管疾病分册,2002；29(3)：145-147.
[73]Appert-Colin A, Cotecchia S, Nenniger-Tosate M, et al. The A-kinase anchoring protein(AKAP) Lbe-signaling complex mediates alphal adrenergic receptor-induced cardiomyocyte hypertrophy[J]. Proc NailAcad Sci USA,2007; 104(24):10140-10145.
[74]The Digitalis investigation Group. The effect of digoxin on mortality and mobidity in patients with heart failure [J]. N Engl J Med,1997; 336:525-533.
[75]Padia SH, Kemp BA, Howell NL, et al. Conversion of renal angiotcnsin II to angiotensin III is critical for A receptor-mediated natriuresis in rats[J]. Hypertension,2008; 51:460-465.
[76]Ramirez-Exposito MJ, Martinez-Martos JM. Hypertension, RAS, and gender: what is the role of aminopeptidases? [J]. Heart Fail Rev,2008; 24[Epub ahead of print].
[77]Banegas I, Prieto I, Vives F, et al. Brain aminopeptidases and Hypertension[J]. J Renin Aldoster syst,2006; 7:129-134.
[78]Landmesser U, Drexler H. Update on inotropic therapy in the management of acute heart failure [J]. Curr Treat Options Cardiovasc Med,2007; 9:443-449.
[79]Archan S, Toiler W. Levosimendan:current status and future prospects[J]. Cur Opin Anaesthesiol,2008; 21:78-84.
[80]NadaI-Ginard B, Kajstura J, Lefi A, et al.Myocyte death, growth, and regeneration in cardiac hypertrophy and failure[J]. Circ Res,2003; 92(2): 139-150.
[81]Chin RC. Bone-marrow stem cells as a source for cell therapy[J]. Heart Fail Rev,2003; 8(3):247-251.
[82]Schwartz Y, Komowski R. Autologous stem cells for functionalmyocardial repair[J]. Heart Fail Rev,2003; 8(3):237-245.
[83]Patel A N, Geffner L, Vina R F, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation:A prospective randomized study[J]. J Thorac Cardiovasc Surg,2005; 130:1631-1638.
[84]Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction[J]. N Engl J Med,2006; 355: 1222-1232.
[85]Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts [J]. Blood,2007; 110:1362-1369.
[86]Fukushima S, Varela-carver A, Coppen R S, et al. Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular
arrhythmias in a rat chronic ichemic heart failure model[J]. Circulation, 2007; 115:2254-2261.
[87]Tura R B, Martino F H, Gowdak H L, et al. Multicenter randomized trial of cell therapy in cardiopathies-miheart study[J]. Trials,2007; 8:2-2.
[88]Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guidehne upgate for the diagnosis and management of chronic heart failure in the adult[J], Circulation,2005; 112(12):e154-235.
[89]Kawabata M, Fantoni C, Regoli F, et al. Activity monitoring in heartfailure patients with cardiac resynchronization therapy [J]. Circ J,2007; 71(12): 1885-1892.
[90]Mark GE, Rhim ES, Feldman AM, et al. Cardiac resynchronization therapy: from creation to evolution-an evidence-based review [J]. Congest Heart fail, 2007; 13(2):84-92.
[91]Hamdan MH, Freedman RA, Gilbert EM, et al. Arrioventricular junction ablation followed by resynchronization therapy in patients with congestive hear failure and atrial fibrillation (AVERT-AF) study design[J]. Pacing Clin Electrophysiol,2006; 29(10):1081-1088.
[92]Ypenburg C, Schalij MJ, Bleeker GB, et al. Impact of viability and scar tissue on reponse to cardiac resynchmnization therapy in ischaemic heart failure patients[J]. Eur Heart J,2007; 28(1):33-41.
[93]Diaz-Infante E, Mont L, Leal J, et al. Predictors of lack response to resynchronization therapy[J]. Am J Cardiol,2005; 95 (12):1436-1440.
[94]赖旭峰,单继军.邓铁涛教授从脾论治慢性充血性心力衰竭经验[J].河北中医.2001；23(12)：909.
[95]尹克春,吴焕林.邓铁涛治疗心力衰竭经验[J].江苏中医药,2002；23(7)：9.
[96]邹旭,吴焕林.邓铁涛教授治疗充血性心力衰竭经验选粹[J].中医药学刊,2004； (4)：583.
[97]柯雪帆.心力衰竭辨证论治的经验体会[J].新疆中医药,1994；(2)：1.
[98]柯雪帆.心力衰竭辨证论治的经验体会(续)[J].新疆中医药,1994；(3)：1.
[99]薛长玲.董燕平治疗慢性心力衰竭经验[J].中医药学刊,2004；17(4)：2250.
[100]黄衍寿,冼绍祥,丁有钦,等.保心康治疗气阳虚型充血性心力衰竭的临床研究[J].中药新药与临床药理,2000；11(5)：261-265.
[101]丁有钦,黄衍寿,冼绍祥,等.强心片治疗胸痹心水证62例临床疗效观察[J].新中医,1998；30(2)：15-17.
[102]刘华荣,刘少波,阮蓉,等.养心康和保心康治疗充血性心力衰竭的临床研究[J].中国临床医学,2001；8(3)：253-254.
[103]陈丽.曲美他嗪治疗慢性心力衰竭患者的疗效观察[J].临床合理用药,2009；2(22)：59-60.
[104]高艳红,李春生,宋亚辉,等.曲美他嗪治疗缺血性心肌病并心力衰竭临床疗效[J].临床医学,2009；29(8)：36-37.
[105]黄衍寿,冼绍祥,吴辉.养心康治疗充血性心力衰竭临床研究[J].中国中西医结合急救杂志,2000；7(2)：71-74.
[106]Mauric PY, Marjorie B, Stuart MC. Comparison of in yivoand in vitro haemodynamic function in experimental heartfailure:use of echocardiography [J]. Cardio Res,1996; 31:873-881.
[107]郑玮,李安华,刘隆忠,等.速度向量成像技术评价阿霉素致兔早期心脏损害左心室收缩同步性的变化[J].中国医学影像技术,2009；25(8)：1335-1338.
[108]黄能慧,周远鹏,刘文化.附子注射液和去甲基乌头碱对心血管作用的比较[J].中国药理学报,1980；(1)：34.
[109]曹小织,张慧敏.慢性充血性心力衰竭大鼠模型的建立[J].内科急危重症杂志,2008;14(6)：296-297.
[110]马力,刘杰,初楠,等.用运动试验评价心力衰竭模型大鼠心功能[J].首都医科大学学报,2007；28(3)：350-354.
[111]莫新玲,谢福生,严冬雪,等.冠状动脉结扎与腹主动脉缩窄所致慢性心力衰竭大鼠模型比较[J].华夏医学,2009；21(1)：4-6.
[112]李书国,毛小波,张峰,等.阿霉素诱导慢性充血性心力衰竭模型制作的改良方案[J].中国比较医学杂志,2006；16(7)：415-418.
[113]冼绍祥,徐志均,黄衍寿,等.养心康对心功能不全动物模型的血流动力学研究[J].中药新药与临床药理,2001；12(2)：91-95.
[114]徐志均.养心康对心衰兔模型的药效学研究[J].中华实用中西医杂志,2005；18(6)：191-193.
[115]陈淑芳,徐卓玉,张婷.脑利钠肽的研究进展[J].齐鲁医学杂志,2005；20(4):367-370.
[116]The Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure[J]. EurHeartJ,2001; 22:1527-1560.
[117]Mukoyama A, Nakao K, Hosoda K, et al. brain natriuretic peptide as a novel cardiac in humans; evidence for an exquisite kual natriuretic peptide system arrial natriuretic peptide and brain natriuretic peptide [J]. J Clin Invest,1991;87(4):1402.
[118]邵宁,徐惠民,吴兆增,等.床旁快速检测BNP鉴别急性呼吸困难的临床意义[J].放射免疫学杂志,2008；21(1)：82-83.
[119]梁孙英,邓珍.血浆脑利钠肽与心力衰竭关系的临床研究[J].临床合理用药.2009,2(12)：15-16.
[120]张丽.心肌cTnI在心血管疾病中的应用[J].心血管病学进展,1997；18(5)：298.
[121]Sato Y, Yamada T, Taniguchi R, et al:Persistently serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes[J]. Circulation,2001; 103:369.
[122]陈群,刘静陆,永怡.慢性心力衰竭患者心肌肌钙蛋白Ⅰ水平与心功能的关[J]系.中国现代医药杂志,2004；6(6)：18-19.
[123]王怡练,孙黎明,王正忠,等.厄贝沙坦对充血性心力衰竭患者cTnI水平及6 min步行试验的影响[J].中西医结合心脑血管病杂志,2009；7(9)：1111-1112.[124]Boddi M.心衰过程中心脏血管紧张素Ⅱ生成与左室功能的关系[J].Circ Res,2001；88(9)：961-968.
[125]廖宝霞,李国锋,郗爱旗.充血性心力衰竭患者血浆sICAM-1与Ang Ⅱ水平变化及相关性探讨[J].山东医药,2008；48(2)：47-48.
[126]杨建峰,魏经汉.慢性心力衰竭患者血清IL-1、TNF-α、血浆Ang Ⅱ含量及临床意义[J].中国医师进修杂志,2007；30(10)：42-44.
[127]Henriksen PA, Newby DE. Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure:cooling an inflamed heart[J]. Heart, 2003; 89(1):14-18.
[128]Bozkurt B, Kribbs SB, Clubb FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor promote progressive left ventricular dysfunction and remodeling in rats[J]. Circulation,1998,97:1382-1391.
[129]唐发宽,华宁,陆宏,等.比索洛尔治疗慢性充血性心力衰竭对血清IL-6和TNF-α水平的影响[J].细胞与分子免疫学杂志,2008；24(12)：1177-1179.
[130]Gupta S, Tripathi CD. Current status of TNF blocking therapy in heart failure[J]. Indian J Med Sci,2005; 59(8):363-366.
[131]张伟英,巢毅,黄琦磊.心功能不全患者血浆TNF-α、IL-6、IL-10水平与心功能状态的关系[J].福建医科大学学报,2007；41(6)：565-567.
[132]陈双庆,杨震.TNF-α和IL-6在慢性心力衰竭中的变化及意义[J].江苏医药,2007; 33 (10):1032-1033.
[133]Cowburn PJ, Cleland JGF. Endothelin antagonists for chronic heart failure:do they have a role[J]. Eur. Heart J,2001; 22:1772-1784.
[134]Thibauh G, Doubell AF, Garcfa R, et al. Endothelin-stimulated secretion of natriuretic peptides by rat atrial myocytes is mediated by endothelin A receptors[J]. Circ Res,1994; 74:460-470.
[135]Kiowski W, Sutsch G, Oechslin E, et al. Hemodynamic efects of bosentan in patients with chronic heart failure [J]. Heart Fail Rev,2001; 6(4):325-334.
[136]郭永霞,冯燕光,魏小刚.血浆内皮素-1、心钠素水平与心功能状态的关系[J].中华临床新医学,2007；7(5)：410-411.
[137]Mcmurray JJV. Heart failure in 10 years time:Focus on pharmacological treatment[J]. Heart,2002; 88(suppl11):1140-1146.
[138]Keith M, Geramayegan A, Sole MJ, et al. Increased oxidative stressin Patients with congestive heart failure [J]. J Am Coil Cardial,1998; 31:1355-1356.
[139]董建文,时安云.超氧化物歧化酶对内皮细胞缺氧复氧损伤的防护作用[J].生理学报,1997；(6)：644-648.
[140]Buffolo RR Jr, Feuerstein GZ. Neurohormonal action, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure [J]. J Cardiovase Pharmacol,1998; 32(suppl):.S22-30.
[141]Tsutsui H, Ide T, HayashidsniS, et al. Great susceptibility of failing cardiac myocytes to oxygen free radical-mediated injury[J]. Cardiovase Res, 2001; 49:103-109.
[142]Grawel S, Wardas M, Niedworok E, et al. Malondialdehyde(MDA) as a lipid peroxidation marker[J]. Wiad Lek,2004; 57(9-10):453-455.
[143]Kerr JFR, Wyllie AH, Currie AR. Apoptosis:a basis biological phenomenon with wide-ranging imp lication in tissue kinetics[J]. B r Cancer,1972; 26: 239.
[144]曹小织,张慧敏.美托洛尔对缺血性心力衰竭大鼠心肌细胞凋亡的影响[J].内科急危重症杂志,2009；15(1)：22-24.
145.刘宗莲,徐淑文.陈鼎祺治疗心力衰竭的经验[J].中医杂志.2000,4(41)：204-205.
[2]严萍,黄飞翔,林求诚,等.B型尿钠肽与充血性心力衰竭中医辨证分型的关系[J].中西医结合心脑血管病杂志,2007；5(5)：380-381.
[3]周杰,高晓玲,张宝州.充血性心力衰竭患者心钠素与中医辨证分型相关性的临床研究[J].中华实用中西医杂志,2003；3(8)：1037-1039.
[4]安辉,林凯旋,缪灿铭.充血性心力衰竭甲状腺激素及中医辨证与疗效相关性的临床研究[J].中国中医药信息杂志,2004；11(7)：618-619.
[5]刘革命,熊尚全,马成富.慢性心力衰竭中医辨证分型与血浆NO及TNF-α含量的关系[J].山东中医杂志,2004；23(2)：71-72.
[6]宋雅芳,杨培君,王瑞莉.仙人救心片对充血性心力衰竭大鼠神经内分泌调节作用的实验研究[J].现代中医药,2006；26(4)：64-65.
[7]朱章志,龙新生.加味真武汤对充血性心衰模型血流动力学及血管紧张素Ⅱ的影响[J].中药新药与临床药理.2001,12(5)：342-345.
[8]张一昕,张志霞,李国川,等.人参强心滴丸对心衰大鼠肾素-血管紧张素-醛固酮系统的影响[J].中药药理与临床,2007；23(2)：70-71.
[9]刘革命,丁磊,谢艳玲,等.康达心口服液对慢性心力衰竭患者血浆肾素-血管紧张素-醛固酮系统的影响[J].吉林中医药,2005；25(4)：12-13.
[10]Greenberg B. J Treatment of heart failure:state of the art and prospectives[J]. J Cardiovasc Pharmacol,2001; 38:S59-S63.
[11]黄飞翔,叶盈,蔡晶,等.健心颗粒干预大鼠慢性心力衰竭左室重构的实验研究[J].中西医结合心脑血管病杂志,2006；4(9)：780-782.
[12]魏聪,贾振华,吴以岭,等.芪苈强心胶囊对兔实验性慢性心力衰竭心室重构的保护作用[J].疑难病杂志,2007；6(3)：144-147.
[13]赵明镜,王硕仁,李敏,等.早期应用活血和益气中药抑制心衰大鼠左室重构和凋亡的对比研究[J].中国中药杂志,2007；32(8)：710-714.
[14]刘革命,郭新侠,谢艳玲,等.温阳益气、活血利水法对慢性心力衰竭左室重构的影响[J].上海中医药杂志,2005；39(5)：20-21.
[15]冼绍祥,欧明.肾阳虚型慢性充血性心力衰竭与TNF-α和IL-6的关系研究[J].实用中医内科杂志,2006；20(6)：564-565.
[16]朱奔奔,郭维,黄亮,等.真武汤对慢性充血性心力衰竭模型大鼠ET、CGRP水平的影响[J].江苏中医药,2005；26(8)：49-51.
[17]黄衍寿,冼绍祥,周名璐,等.养心康对心肌肥大型心力衰竭大鼠血浆ET、CGRP 含量的影响[J].广州中医药大学学报,2002；19(1)：40-42.
[18]王敬民,金炜,孙秀笺.参麦注射液对心力衰竭患者血ET及TNF-α的影响[J].浙江中西医结合杂志,2004；14(1)：4-6.
[19]Li Z, Bimg OH, long X, et al. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat[J]. Am J Physiol,1997; 272:H2313.
[20]方显明,韦斌,郎中云.安心颗粒对心力衰竭大鼠细胞凋亡基因Bcl—2及Fas表达的影响[J].中西医结合心脑血管病杂志,2007；5(8)：701-702.
[21]李敏,王硕仁,赵明镜,等.活血益气方药对心肌梗死后心力衰竭大鼠心肌细胞凋亡的影响[J].中西医结合心脑血管病杂志,2005；3(1)：33-35.
[22]陈兆善,董耀荣,周华,等.强心合剂对慢性心力衰竭大鼠心肌细胞凋亡的影响[J].上海中医药大学学报,2004；18(1)：42-45.
[23]刘艳,陈丽云,章忱.慢性心力衰竭中医证型的文献分析[J].上海中医药大学学报,2008；22(4)：43-46.
[24]邓铁涛.治疗心力衰竭的思路与方法[J].新中医,1995； (1)：6-8.
[25]邹旭,刘泽银,潘光明.暖心胶囊治疗慢性充血性心力衰竭的远期疗效观察[J].上海中医药杂志,2006；40(2)：6-7.
[26]杨培君,杨磊.充血性心力衰竭的中医治疗概要[J].陕西中医学院学报,2002；25(1)：2-5.
[27]陈长华.辨证施治心力衰竭50例[J].福建中医学院学报,1995；5(1)：14-15.
[28]谢乐.中医分型治疗充血性心力衰竭77例[J].四川中医,2002；20(6)：41.
[29]张瑞华,焦增绵,马丽红,等.慢性充血性心力衰竭的中医辨证论治[J].中国医药学报,2002；17(17)：440.
[30]王双乾,梁栋贤.心衰饮治疗心力衰竭32例[J].陕西中医,2002；23(6)：506.
[31]吴勉华.养心通脉合剂治疗充血性心力衰竭临床研究[J].山东中医杂志,2001；20(12)：715-718.
[32]张万义,邱云卿,张万芬.升补宗气法治疗老年慢性充血性心力衰竭疗效观察[J].中国中西医结合杂志,2004；24(1)：43.
[33]郑军.温阳利水法治疗慢性心力衰竭48例[J].陕西中医,2005；26(2)：102-103.
[34]赵惠,李七一.真武汤加味治疗慢性充血性心力衰竭40例[J].南京中医药大学学报,2005；21(6)：355-356.
[35]孙媛.中西医结合治疗慢性充血性心力衰竭32例[J].吉林中医药,2005；25(6)：32-33.
[36]李金红.中西医结合治疗充血性心力衰竭临床观察[J].辽宁中医杂志,2006；33(7)：860-861.
[37]朱丽华,倪国瑞.中西医结合治疗慢性心力衰竭30例疗效观察[J].新中医,2007；39(11)：17-18.
[38]陈勇.加味真武汤治疗慢性心衰50例临床观察[J].光明中医,2006；21(7)：34-36.
[39]王敏生.温阳强心汤治疗慢性心衰30例[J].实用中医内科杂志,2005；19(6)：557.
[40]杨勇娟.黄芪注射液结合西药治疗充血性心力衰竭的疗效观察[J]. World Health Digest,2007; 4 (11):31-32.
[41]孟捍华,马敏杰.黄芪注射液对慢性充血性心力衰竭治疗作用的观察[J].中医药临床杂志,2008；20(1)：41-42.
[42]张继明,侯召荣.培哚普利加黄芪注射液治疗难治性心力衰竭疗效观察[J].中国心血管杂志,2006；11(6)：451-453.
[43]刘英芹,李芸.黄芪注射液治疗充血性心力衰竭临床研究[J].实用中医药杂志,2005：21(4)：198-199.
[44]李有亮.川芎嗪联合黄芪治疗慢性肺心病并发心衰患者52例临床观察[J].中华现代内科学杂志,2004；1(5)：56-58.
[45]程勇,郑金荣,王兵,等.川芎嗪治疗56例肺心病心衰患者的临床观察[J].中原医刊,2007；34(5)：77-78.
[46]吴晓玲.葶苈子水提物对狗左心室功能的作用[J].中药材,1998；21(5)：243-245.
[47]柏正平.复方葶苈子胶囊对肺动脉高压和心肌力影响的实验研究[J].湖南中医杂志,2000：16(1)：57.
[48]戚文航.心力衰竭的流行病学及治疗进展[J].现代实用医学,2004；16(11)：632-634.
[49]Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol,1993; 22(supplA):6A-13A.
[50]Michael B. Circulation,2003; 107:11002-11021.
[51]魏晓萍,陈雅慧,惠起源.β3肾上腺素能受体与心血管疾病[J].心血管病学进展,2005；26(2)：204-206.
[52]李为民,孔一慧,薛竟宜,田颖.NG-硝基-L-精氨酸甲基酯对心力衰竭大鼠应用β3受体激动剂后血流动力学和β受体mRNA表达水平的影响[J].中华心血管病杂志,2005：33(6)：509-512.
[53]李美霞,王晓樑,汤嘉宁,等.心力衰竭患者抗β3肾上腺素能受体自身抗体的分布及特性[J].中华心血管病杂志,2005；33(12)：1114-1119.
[54]富路,葛海龙,李佳,等.慢性心力衰竭患者血钠水平与血浆肾素活性、抗利尿激素、脑利钠肽的关系[J].中华心血管病杂志,2006；34(9)：781-783.
[55]王礼春,马虹,何建桂,等.培哚普利对心力衰竭大鼠心肌细胞钙瞬变及其调控蛋白的影响[J].中华心血管病杂志,2005；33(6)：513-518.
[56]杨永健,朱文玲,周兴文,等.钙蛋白酶参与心力衰竭患者心肌重构的信号传导[J].中华心血管病杂志,2005；33(3)：247-250.
[57]杨永健,张鑫,朱文玲,等.钙调神经磷酸酶信号通路参与充血性心力衰竭患者心肌重塑的机制[J].中国循环杂志,2006；21(4)：291-293.
[58]刘尊齐,崔连群.慢性心力衰竭患者血清肌钙蛋白Ⅰ与心肌重构的相关性研究[J].中华心血管病杂志,2006；34(5)：437-439.
[59]郭豫涛,李小鹰,吴迪,等.骨髓干细胞移植通过基质金属蛋白酶及其抑制剂降低大鼠缺血性心力衰竭心室重构[J].中华心血管病杂志,2006；34(9)：784-788.
[60]Foo RS, Mani K, Kitsis RN. Death begets failure in the heart[J]. J Clin Invest,2005; 115(3):565-571.
[61]Merkle S, Frantz S, Schon MP, et al. A role for caspase-1 in heart failure[J]. Cite Res,2007; 100(5):645-653.
[62]Yam aguchiH, Yoshida J, Y am am o to K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy [J]. J Am CollCardiol,2004; 43:55-60.
[63]崔红玉,王曼,赵常艳,等.B型尿钠肽与不同心功能分级的充血性心力衰竭的关系[J].中国心血管杂志,2005；10(5)：317-318.
[64]汪芳,李卫,黄洁,等.血浆N末端原脑利钠肽水平对慢性心力衰竭患者长期预后的预测价值[J].中华心血管病杂志,2006；34(1)：28-32.
[65]初红霞,陶志刚,梁荔燕.心力衰竭患者血清血管内皮生长因子和C-反应蛋白的变化及意义[J].中国心血管杂志,2006；11(6)：439-442.
[66]Sun M, Chen M, Dawood F, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state[J]. Circulation,2007; 115(11):1398-1407.
[67]Handek SB, Taffet GE, Schneider MD, et al. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways[J]. J Clin Invest,2007; 117(9):2692-2701.
[68]李安莹,谭茗月,赵水平.心力衰竭患者循环血中肿瘤坏死因子-α、白细胞介素-6、高敏C反应蛋白水平的变化及阿托伐他汀的干预作用[J].中国循环杂志,2006；21(6)：435-437.
[69]任骞,刘玉杰.充血性心力衰竭患者甲状腺激素异常变化及其临床意义[J].中国心血管杂志,2006；11(3)：189-190.
[70]中华医学会心血管病学分会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂 志,2007；35(12)：1076-1095.
[71]Brown NJ. AgirbastiMA. Williams GH. et al. Effect of Activation and Inhibition of Renin-angiotension System on Plasma PAF1[J]. Hyperten slon, 1998; 32 (6):965-971.
[72]孟伟栋, 汪爱虎.醛固酮及拮抗剂在心力衰竭中的研究进展[J].国外医学心血管疾病分册,2002；29(3)：145-147.
[73]Appert-Colin A, Cotecchia S, Nenniger-Tosate M, et al. The A-kinase anchoring protein(AKAP) Lbe-signaling complex mediates alphal adrenergic receptor-induced cardiomyocyte hypertrophy[J]. Proc NailAcad Sci USA,2007; 104(24):10140-10145.
[74]The Digitalis investigation Group. The effect of digoxin on mortality and mobidity in patients with heart failure [J]. N Engl J Med,1997; 336:525-533.
[75]Padia SH, Kemp BA, Howell NL, et al. Conversion of renal angiotcnsin II to angiotensin III is critical for A receptor-mediated natriuresis in rats[J]. Hypertension,2008; 51:460-465.
[76]Ramirez-Exposito MJ, Martinez-Martos JM. Hypertension, RAS, and gender: what is the role of aminopeptidases? [J]. Heart Fail Rev,2008; 24[Epub ahead of print].
[77]Banegas I, Prieto I, Vives F, et al. Brain aminopeptidases and Hypertension[J]. J Renin Aldoster syst,2006; 7:129-134.
[78]Landmesser U, Drexler H. Update on inotropic therapy in the management of acute heart failure [J]. Curr Treat Options Cardiovasc Med,2007; 9:443-449.
[79]Archan S, Toiler W. Levosimendan:current status and future prospects[J]. Cur Opin Anaesthesiol,2008; 21:78-84.
[80]NadaI-Ginard B, Kajstura J, Lefi A, et al.Myocyte death, growth, and regeneration in cardiac hypertrophy and failure[J]. Circ Res,2003; 92(2): 139-150.
[81]Chin RC. Bone-marrow stem cells as a source for cell therapy[J]. Heart Fail Rev,2003; 8(3):247-251.
[82]Schwartz Y, Komowski R. Autologous stem cells for functionalmyocardial repair[J]. Heart Fail Rev,2003; 8(3):237-245.
[83]Patel A N, Geffner L, Vina R F, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation:A prospective randomized study[J]. J Thorac Cardiovasc Surg,2005; 130:1631-1638.
[84]Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction[J]. N Engl J Med,2006; 355: 1222-1232.
[85]Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts [J]. Blood,2007; 110:1362-1369.
[86]Fukushima S, Varela-carver A, Coppen R S, et al. Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular
arrhythmias in a rat chronic ichemic heart failure model[J]. Circulation, 2007; 115:2254-2261.
[87]Tura R B, Martino F H, Gowdak H L, et al. Multicenter randomized trial of cell therapy in cardiopathies-miheart study[J]. Trials,2007; 8:2-2.
[88]Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guidehne upgate for the diagnosis and management of chronic heart failure in the adult[J], Circulation,2005; 112(12):e154-235.
[89]Kawabata M, Fantoni C, Regoli F, et al. Activity monitoring in heartfailure patients with cardiac resynchronization therapy [J]. Circ J,2007; 71(12): 1885-1892.
[90]Mark GE, Rhim ES, Feldman AM, et al. Cardiac resynchronization therapy: from creation to evolution-an evidence-based review [J]. Congest Heart fail, 2007; 13(2):84-92.
[91]Hamdan MH, Freedman RA, Gilbert EM, et al. Arrioventricular junction ablation followed by resynchronization therapy in patients with congestive hear failure and atrial fibrillation (AVERT-AF) study design[J]. Pacing Clin Electrophysiol,2006; 29(10):1081-1088.
[92]Ypenburg C, Schalij MJ, Bleeker GB, et al. Impact of viability and scar tissue on reponse to cardiac resynchmnization therapy in ischaemic heart failure patients[J]. Eur Heart J,2007; 28(1):33-41.
[93]Diaz-Infante E, Mont L, Leal J, et al. Predictors of lack response to resynchronization therapy[J]. Am J Cardiol,2005; 95 (12):1436-1440.
[94]赖旭峰,单继军.邓铁涛教授从脾论治慢性充血性心力衰竭经验[J].河北中医.2001；23(12)：909.
[95]尹克春,吴焕林.邓铁涛治疗心力衰竭经验[J].江苏中医药,2002；23(7)：9.
[96]邹旭,吴焕林.邓铁涛教授治疗充血性心力衰竭经验选粹[J].中医药学刊,2004； (4)：583.
[97]柯雪帆.心力衰竭辨证论治的经验体会[J].新疆中医药,1994；(2)：1.
[98]柯雪帆.心力衰竭辨证论治的经验体会(续)[J].新疆中医药,1994；(3)：1.
[99]薛长玲.董燕平治疗慢性心力衰竭经验[J].中医药学刊,2004；17(4)：2250.
[100]黄衍寿,冼绍祥,丁有钦,等.保心康治疗气阳虚型充血性心力衰竭的临床研究[J].中药新药与临床药理,2000；11(5)：261-265.
[101]丁有钦,黄衍寿,冼绍祥,等.强心片治疗胸痹心水证62例临床疗效观察[J].新中医,1998；30(2)：15-17.
[102]刘华荣,刘少波,阮蓉,等.养心康和保心康治疗充血性心力衰竭的临床研究[J].中国临床医学,2001；8(3)：253-254.
[103]陈丽.曲美他嗪治疗慢性心力衰竭患者的疗效观察[J].临床合理用药,2009；2(22)：59-60.
[104]高艳红,李春生,宋亚辉,等.曲美他嗪治疗缺血性心肌病并心力衰竭临床疗效[J].临床医学,2009；29(8)：36-37.
[105]黄衍寿,冼绍祥,吴辉.养心康治疗充血性心力衰竭临床研究[J].中国中西医结合急救杂志,2000；7(2)：71-74.
[106]Mauric PY, Marjorie B, Stuart MC. Comparison of in yivoand in vitro haemodynamic function in experimental heartfailure:use of echocardiography [J]. Cardio Res,1996; 31:873-881.
[107]郑玮,李安华,刘隆忠,等.速度向量成像技术评价阿霉素致兔早期心脏损害左心室收缩同步性的变化[J].中国医学影像技术,2009；25(8)：1335-1338.
[108]黄能慧,周远鹏,刘文化.附子注射液和去甲基乌头碱对心血管作用的比较[J].中国药理学报,1980；(1)：34.
[109]曹小织,张慧敏.慢性充血性心力衰竭大鼠模型的建立[J].内科急危重症杂志,2008;14(6)：296-297.
[110]马力,刘杰,初楠,等.用运动试验评价心力衰竭模型大鼠心功能[J].首都医科大学学报,2007；28(3)：350-354.
[111]莫新玲,谢福生,严冬雪,等.冠状动脉结扎与腹主动脉缩窄所致慢性心力衰竭大鼠模型比较[J].华夏医学,2009；21(1)：4-6.
[112]李书国,毛小波,张峰,等.阿霉素诱导慢性充血性心力衰竭模型制作的改良方案[J].中国比较医学杂志,2006；16(7)：415-418.
[113]冼绍祥,徐志均,黄衍寿,等.养心康对心功能不全动物模型的血流动力学研究[J].中药新药与临床药理,2001；12(2)：91-95.
[114]徐志均.养心康对心衰兔模型的药效学研究[J].中华实用中西医杂志,2005；18(6)：191-193.
[115]陈淑芳,徐卓玉,张婷.脑利钠肽的研究进展[J].齐鲁医学杂志,2005；20(4):367-370.
[116]The Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure[J]. EurHeartJ,2001; 22:1527-1560.
[117]Mukoyama A, Nakao K, Hosoda K, et al. brain natriuretic peptide as a novel cardiac in humans; evidence for an exquisite kual natriuretic peptide system arrial natriuretic peptide and brain natriuretic peptide [J]. J Clin Invest,1991;87(4):1402.
[118]邵宁,徐惠民,吴兆增,等.床旁快速检测BNP鉴别急性呼吸困难的临床意义[J].放射免疫学杂志,2008；21(1)：82-83.
[119]梁孙英,邓珍.血浆脑利钠肽与心力衰竭关系的临床研究[J].临床合理用药.2009,2(12)：15-16.
[120]张丽.心肌cTnI在心血管疾病中的应用[J].心血管病学进展,1997；18(5)：298.
[121]Sato Y, Yamada T, Taniguchi R, et al:Persistently serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes[J]. Circulation,2001; 103:369.
[122]陈群,刘静陆,永怡.慢性心力衰竭患者心肌肌钙蛋白Ⅰ水平与心功能的关[J]系.中国现代医药杂志,2004；6(6)：18-19.
[123]王怡练,孙黎明,王正忠,等.厄贝沙坦对充血性心力衰竭患者cTnI水平及6 min步行试验的影响[J].中西医结合心脑血管病杂志,2009；7(9)：1111-1112.[124]Boddi M.心衰过程中心脏血管紧张素Ⅱ生成与左室功能的关系[J].Circ Res,2001；88(9)：961-968.
[125]廖宝霞,李国锋,郗爱旗.充血性心力衰竭患者血浆sICAM-1与Ang Ⅱ水平变化及相关性探讨[J].山东医药,2008；48(2)：47-48.
[126]杨建峰,魏经汉.慢性心力衰竭患者血清IL-1、TNF-α、血浆Ang Ⅱ含量及临床意义[J].中国医师进修杂志,2007；30(10)：42-44.
[127]Henriksen PA, Newby DE. Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure:cooling an inflamed heart[J]. Heart, 2003; 89(1):14-18.
[128]Bozkurt B, Kribbs SB, Clubb FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor promote progressive left ventricular dysfunction and remodeling in rats[J]. Circulation,1998,97:1382-1391.
[129]唐发宽,华宁,陆宏,等.比索洛尔治疗慢性充血性心力衰竭对血清IL-6和TNF-α水平的影响[J].细胞与分子免疫学杂志,2008；24(12)：1177-1179.
[130]Gupta S, Tripathi CD. Current status of TNF blocking therapy in heart failure[J]. Indian J Med Sci,2005; 59(8):363-366.
[131]张伟英,巢毅,黄琦磊.心功能不全患者血浆TNF-α、IL-6、IL-10水平与心功能状态的关系[J].福建医科大学学报,2007；41(6)：565-567.
[132]陈双庆,杨震.TNF-α和IL-6在慢性心力衰竭中的变化及意义[J].江苏医药,2007; 33 (10):1032-1033.
[133]Cowburn PJ, Cleland JGF. Endothelin antagonists for chronic heart failure:do they have a role[J]. Eur. Heart J,2001; 22:1772-1784.
[134]Thibauh G, Doubell AF, Garcfa R, et al. Endothelin-stimulated secretion of natriuretic peptides by rat atrial myocytes is mediated by endothelin A receptors[J]. Circ Res,1994; 74:460-470.
[135]Kiowski W, Sutsch G, Oechslin E, et al. Hemodynamic efects of bosentan in patients with chronic heart failure [J]. Heart Fail Rev,2001; 6(4):325-334.
[136]郭永霞,冯燕光,魏小刚.血浆内皮素-1、心钠素水平与心功能状态的关系[J].中华临床新医学,2007；7(5)：410-411.
[137]Mcmurray JJV. Heart failure in 10 years time:Focus on pharmacological treatment[J]. Heart,2002; 88(suppl11):1140-1146.
[138]Keith M, Geramayegan A, Sole MJ, et al. Increased oxidative stressin Patients with congestive heart failure [J]. J Am Coil Cardial,1998; 31:1355-1356.
[139]董建文,时安云.超氧化物歧化酶对内皮细胞缺氧复氧损伤的防护作用[J].生理学报,1997；(6)：644-648.
[140]Buffolo RR Jr, Feuerstein GZ. Neurohormonal action, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure [J]. J Cardiovase Pharmacol,1998; 32(suppl):.S22-30.
[141]Tsutsui H, Ide T, HayashidsniS, et al. Great susceptibility of failing cardiac myocytes to oxygen free radical-mediated injury[J]. Cardiovase Res, 2001; 49:103-109.
[142]Grawel S, Wardas M, Niedworok E, et al. Malondialdehyde(MDA) as a lipid peroxidation marker[J]. Wiad Lek,2004; 57(9-10):453-455.
[143]Kerr JFR, Wyllie AH, Currie AR. Apoptosis:a basis biological phenomenon with wide-ranging imp lication in tissue kinetics[J]. B r Cancer,1972; 26: 239.
[144]曹小织,张慧敏.美托洛尔对缺血性心力衰竭大鼠心肌细胞凋亡的影响[J].内科急危重症杂志,2009；15(1)：22-24.
145.刘宗莲,徐淑文.陈鼎祺治疗心力衰竭的经验[J].中医杂志.2000,4(41)：204-205.